FDA Conditionally Approves Drug for Management of Ventricular Hypertrophy in Cats

Today, the U.S. Food and Drug Administration is announcing the conditional approval of Felycin-CA1 (sirolimus delayed-release tablets) for the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM). This is the first product approved for use in cats with HCM for any indication.